Valuation: Lundbeck

Market Cap 53.17B 7.94B 7.11B 6.54B 5.93B 11.08B 754B 11.29B 78.02B 31.32B 397B 29.8B 29.17B 1,251B P/E 2026 *
11.8x
P/E 2027 * 11.7x
Enterprise Value 57.1B 8.53B 7.64B 7.03B 6.37B 11.9B 810B 12.12B 83.78B 33.63B 426B 32.01B 31.33B 1,343B EV / Sales 2026 *
2.2x
EV / Sales 2027 * 2.01x
Free-Float
30.74%
Yield 2026 *
2.88%
Yield 2027 * 2.54%
1 day+1.32%
1 week+1.83%
1 month+21.36%
3 months+38.89%
6 months+42.86%
Current year+38.12%
1 week 48.3
Extreme 48.3
50.2
1 month 41.85
Extreme 41.85
50.2
Current year 31.4
Extreme 31.4
50.2
1 year 31.4
Extreme 31.4
50.2
3 years 23.3
Extreme 23.3
50.2
5 years 21.94
Extreme 21.935
50.2
10 years 21.94
Extreme 21.935
50.2
Manager TitleAgeSince
Chief Executive Officer 59 30/09/2023
Director of Finance/CFO 49 31/08/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 24/03/2015
Director/Board Member 67 24/03/2015
Director/Board Member 60 19/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.32%+1.83% - - 7.94B
+3.19%+11.31%+64.28%+155.66% 1,263B
-0.73%+3.56%+44.65%+83.74% 658B
+1.41%+3.24%+35.25%+106.98% 521B
+0.42%+3.20%+55.81%+69.71% 391B
+2.18%+2.93%+73.90%+45.38% 369B
+1.12%+4.52%+34.76%+57.00% 307B
+6.96%+8.86%+11.95%+35.06% 290B
+1.15%+6.09%+56.15%+78.66% 252B
+3.06%+9.38%+42.48%+112.84% 212B
Average +2.01%+5.90%+46.58%+82.78% 473.55B
Weighted average by Cap. +2.01%+6.60%+50.51%+99.19%

Financials

2026 *2027 *
Net sales 26B 3.88B 3.48B 3.2B 2.9B 5.42B 369B 5.52B 38.15B 15.31B 194B 14.57B 14.26B 612B 26.29B 3.93B 3.52B 3.23B 2.93B 5.48B 373B 5.58B 38.57B 15.48B 196B 14.74B 14.42B 618B
Net income 4.62B 690M 618M 569M 515M 963M 65.53B 981M 6.78B 2.72B 34.47B 2.59B 2.53B 109B 4.67B 697M 625M 575M 521M 973M 66.23B 991M 6.85B 2.75B 34.84B 2.62B 2.56B 110B
Net Debt 3.93B 587M 526M 484M 438M 819M 55.75B 835M 5.77B 2.32B 29.33B 2.2B 2.16B 92.49B -218M -32.57M -29.17M -26.83M -24.31M -45.44M -3.09B -46.29M -320M -128M -1.63B -122M -120M -5.13B
Projected Income Statement - Annual - Lundbeck
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
30/10/26 DKK 50.00 +1.32% 88,384
29/10/26 DKK 49.35 +1.65% 121,332
28/10/26 DKK 48.55 -.--% 44,208
27/10/26 DKK 48.55 -0.61% 52,354
26/10/26 DKK 48.85 -0.51% 73,099
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Lundbeck
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
54.55DKK
Average target price
50.12DKK
Spread / Average Target
-8.11%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lundbeck